Compare QIAGEN NV with Similar Stocks
Dashboard
1
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.91 times
2
Poor long term growth as Operating profit has grown by an annual rate 5.15% of over the last 5 years
3
Positive results in Jun 25
4
With ROCE of 13.55%, it has a very expensive valuation with a 2.70 Enterprise value to Capital Employed
5
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
USD 11,466 Million (Small Cap)
20.00
NA
2.71%
0.12
12.44%
3.14
Revenue and Profits:
Net Sales:
533 Million
(Quarterly Results - Sep 2025)
Net Profit:
130 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
43.02%
0%
43.02%
6 Months
17.38%
0%
17.38%
1 Year
20.49%
0%
20.49%
2 Years
15.82%
0%
15.82%
3 Years
16.87%
0%
16.87%
4 Years
9.92%
0%
9.92%
5 Years
20.17%
0%
20.17%
QIAGEN NV for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
4.83%
EBIT Growth (5y)
5.15%
EBIT to Interest (avg)
10.44
Debt to EBITDA (avg)
0.91
Net Debt to Equity (avg)
0.13
Sales to Capital Employed (avg)
0.38
Tax Ratio
32.32%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
77.97%
ROCE (avg)
13.81%
ROE (avg)
14.15%
Valuation key factors
Factor
Value
P/E Ratio
20
Industry P/E
Price to Book Value
2.93
EV to EBIT
19.95
EV to EBITDA
14.57
EV to Capital Employed
2.70
EV to Sales
5.20
PEG Ratio
0.59
Dividend Yield
2.96%
ROCE (Latest)
13.55%
ROE (Latest)
14.47%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 83 Schemes (31.21%)
Foreign Institutions
Held by 213 Foreign Institutions (28.63%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
532.60
533.50
-0.17%
Operating Profit (PBDIT) excl Other Income
188.30
185.50
1.51%
Interest
8.20
7.60
7.89%
Exceptional Items
-8.10
-14.10
42.55%
Consolidate Net Profit
130.00
96.20
35.14%
Operating Profit Margin (Excl OI)
257.80%
254.90%
0.29%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is -0.17% vs 10.34% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 35.14% vs 5.95% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,978.20
1,965.30
0.66%
Operating Profit (PBDIT) excl Other Income
698.20
650.60
7.32%
Interest
43.80
53.40
-17.98%
Exceptional Items
-405.60
-47.30
-757.51%
Consolidate Net Profit
83.60
341.30
-75.51%
Operating Profit Margin (Excl OI)
250.20%
226.60%
2.36%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 0.66% vs -8.23% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -75.51% vs -19.35% in Dec 2023
About QIAGEN NV 
QIAGEN NV
Pharmaceuticals & Biotechnology
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Company Coordinates 
Company Details
Hulsterweg 82 , VENLO None : 5912 PL
Registrar Details






